Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer

TL;DR

This paper reviews how anti-EGFR antibodies like cetuximab and panitumumab are used to treat advanced colorectal cancer, including their history, current use, and future research directions.

Contribution

The paper offers a comprehensive review of anti-EGFR antibody use in colorectal cancer, highlighting clinical implications and future research opportunities.

Findings

Anti-EGFR antibodies are part of standard care for advanced colorectal cancer.

Biomarkers influence treatment decisions and dosing strategies.

Future research explores combinations with MAPK-targeted therapies and immunotherapy.

Abstract

Colorectal cancer is the third most common cancer worldwide, and incidence is rising in younger individuals. Anti-EGFR antibodies, including cetuximab and panitumumab, have been incorporated into standard-of-care practice for patients with advanced disease. Herein, we review the molecular characteristics of these agents and the trials that lead to their approvals. Further, we discuss clinical implications of data regarding biomarkers that dictate treatment selection, different dosing strategies, and side effect management. Finally, we look towards the future and describe contexts in which these agents are currently being investigated clinically with a focus on combinations with MAPK-targeted therapies and immunotherapy. Overall, this review provides historical context, current clinical usage, and future directions for anti-EGFR antibodies in advanced colorectal cancer.

This review provides historical context, current clinical usage, and future directions for anti-EGFR antibodies in advanced colorectal cancer.

Figures